Darunavir (Prezista) for HIV infection.  [electronic resource] 

 -  The Medical letter on drugs and therapeutics  Sep 2006 
 - 74-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0025-732X 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antiretroviral Therapy, Highly Active--methods<br/>Biological Availability<br/>Blood Proteins--metabolism<br/>Cytochrome P-450 CYP3A--metabolism<br/>Cytochrome P-450 CYP3A Inhibitors<br/>Darunavir<br/>Drug Approval<br/>Drug Interactions<br/>Drug Resistance, Viral<br/>Enfuvirtide<br/>HIV Envelope Protein gp41--pharmacology<br/>HIV Infections--drug therapy<br/>HIV Protease Inhibitors--pharmacokinetics<br/>HIV-1--drug effects<br/>Humans<br/>Peptide Fragments--pharmacology<br/>Protein Binding--drug effects<br/>RNA, Viral--blood<br/>Randomized Controlled Trials as Topic--methods<br/>Ritonavir--pharmacology<br/>Sulfonamides--pharmacokinetics<br/>Tablets<br/>Time Factors<br/>United States<br/>Viral Load